EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort

Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR)) sc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2019-12, Vol.11 (12), p.1954
Hauptverfasser:	Prelaj, Arsela, Ferrara, Roberto, Rebuzzi, Sara Elena, Proto, Claudia, Signorelli, Diego, Galli, Giulia, De Toma, Alessandro, Randon, Giovanni, Pagani, Filippo, Viscardi, Giuseppe, Brambilla, Marta, Trevisan, Benedetta, Ganzinelli, Monica, Martinetti, Antonia, Gallucci, Rosaria, Di Mauro, Rosa Maria, Molino, Giuliano, Zilembo, Nicoletta, Torri, Valter, de Braud, Filippo Maria, Garassino, Marina Chiara, Lo Russo, Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Biomarkers Cancer therapies Chemotherapy Clinical medicine Clinical trials Histology Immune checkpoint inhibitors Immune system Immunotherapy L-Lactate dehydrogenase Lactic acid Leukocytes (neutrophilic) Liver Lung cancer Lymphocytes Medical prognosis Melanoma Metastases Metastasis Non-small cell lung carcinoma PD-L1 protein Smoking Survival analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!